Fulgent Genetics (NASDAQ:FLGT) Stock Price Up 7.3% – Here’s What Happened

07 Jan 2026, 15:42 by Amy Steele · The Cerbat Gem

Fulgent Genetics, Inc. (NASDAQ:FLGT – Get Free Report) shares were up 7.3% on Wednesday . The company traded as high as $27.99 and last traded at $27.8950. Approximately 186,325 shares changed hands during trading, a decline of 4% from the average daily volume of 193,431 shares. The stock had previously closed at $25.99.

Analyst Upgrades and Downgrades

Several brokerages have commented on FLGT. Raymond James Financial restated an “outperform” rating and issued a $36.00 price objective on shares of Fulgent Genetics in a report on Friday, November 14th. Piper Sandler increased their target price on Fulgent Genetics from $21.00 to $30.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 11th. Wall Street Zen cut Fulgent Genetics from a “buy” rating to a “hold” rating in a research note on Saturday, December 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Fulgent Genetics in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $32.00.

Read Our Latest Stock Analysis on FLGT

Fulgent Genetics Stock Performance

The stock has a market capitalization of $862.70 million, a P/E ratio of -20.08 and a beta of 0.63. The business has a 50-day moving average price of $27.18 and a 200 day moving average price of $23.23.

Fulgent Genetics (NASDAQ:FLGT – Get Free Report) last posted its quarterly earnings data on Friday, November 7th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.36. The company had revenue of $84.07 million during the quarter, compared to analyst estimates of $81.43 million. Fulgent Genetics had a negative return on equity of 2.55% and a negative net margin of 13.62%.Fulgent Genetics has set its FY 2025 guidance at 0.300-0.300 EPS. As a group, research analysts forecast that Fulgent Genetics, Inc. will post -0.85 earnings per share for the current fiscal year.

Insider Activity

In other Fulgent Genetics news, COO Jian Xie sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, November 19th. The shares were sold at an average price of $29.10, for a total transaction of $291,000.00. Following the completion of the sale, the chief operating officer directly owned 349,768 shares in the company, valued at approximately $10,178,248.80. This trade represents a 2.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Hanlin Gao sold 1,075 shares of Fulgent Genetics stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $28.33, for a total transaction of $30,454.75. Following the completion of the transaction, the insider directly owned 952,890 shares of the company’s stock, valued at $26,995,373.70. This trade represents a 0.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 15,572 shares of company stock valued at $454,112. 33.11% of the stock is owned by insiders.

Institutional Investors Weigh In On Fulgent Genetics

A number of institutional investors have recently made changes to their positions in FLGT. Acadian Asset Management LLC lifted its holdings in shares of Fulgent Genetics by 124.0% during the 1st quarter. Acadian Asset Management LLC now owns 805,941 shares of the company’s stock valued at $13,611,000 after buying an additional 446,076 shares during the period. Millennium Management LLC lifted its holdings in Fulgent Genetics by 28.6% in the first quarter. Millennium Management LLC now owns 1,969,433 shares of the company’s stock valued at $33,283,000 after acquiring an additional 437,632 shares during the period. JPMorgan Chase & Co. lifted its holdings in Fulgent Genetics by 767.0% in the third quarter. JPMorgan Chase & Co. now owns 299,014 shares of the company’s stock valued at $6,758,000 after acquiring an additional 264,524 shares during the period. Diametric Capital LP purchased a new position in Fulgent Genetics in the second quarter worth about $3,359,000. Finally, Brandywine Global Investment Management LLC bought a new stake in shares of Fulgent Genetics during the 2nd quarter valued at about $2,678,000. Hedge funds and other institutional investors own 48.06% of the company’s stock.

Fulgent Genetics Company Profile

(Get Free Report)

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.